Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Abou-Alfa G. K., Meyer T., Cheng A., El-Khoueiry A. B., Rimassa L., Ryoo B., ...More

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Volume: 36
• Doi Number: 10.1200/jco.2018.36.4_suppl.207
• City: San-Francisco
• Country: Costa Rica
• Trakya University Affiliated: Yes